BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35862151)

  • 1. Assessment of Clinical Worsening End Points as a Surrogate for Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Tremblay É; Gosselin C; Mai V; Lajoie AC; Kilo R; Weatherald J; Lacasse Y; Bonnet S; Lega JC; Provencher S
    Circulation; 2022 Aug; 146(8):597-612. PubMed ID: 35862151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is low-risk status a surrogate outcome in pulmonary arterial hypertension? An analysis of three randomised trials.
    Blette BS; Moutchia J; Al-Naamani N; Ventetuolo CE; Cheng C; Appleby D; Urbanowicz RJ; Fritz J; Mazurek JA; Li F; Kawut SM; Harhay MO
    Lancet Respir Med; 2023 Oct; 11(10):873-882. PubMed ID: 37230098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Worsening as Composite Study End Point in Pediatric Pulmonary Arterial Hypertension.
    Ploegstra MJ; Arjaans S; Zijlstra WMH; Douwes JM; Vissia-Kazemier TR; Roofthooft MTR; Hillege HL; Berger RMF
    Chest; 2015 Sep; 148(3):655-666. PubMed ID: 25741884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trial Duration and Risk Reduction in Combination Therapy Trials for Pulmonary Arterial Hypertension: A Systematic Review.
    Lajoie AC; Guay CA; Lega JC; Lauzière G; Simard S; Lambert C; Lacasse Y; Bonnet S; Provencher S
    Chest; 2018 May; 153(5):1142-1152. PubMed ID: 29175359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension.
    Fox BD; Shimony A; Langleben D
    Am J Cardiol; 2011 Oct; 108(8):1177-82. PubMed ID: 21864815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of oral targeted therapies in pulmonary arterial hypertension: a meta-analysis of randomized clinical trials.
    Zheng YG; Ma H; Chen L; Jiang XM; Zhou L; Lin S; Chen SL
    Pulm Circ; 2018; 8(4):2045894018798183. PubMed ID: 30124134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac-MRI Predicts Clinical Worsening and Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.
    Alabed S; Shahin Y; Garg P; Alandejani F; Johns CS; Lewis RA; Condliffe R; Wild JM; Kiely DG; Swift AJ
    JACC Cardiovasc Imaging; 2021 May; 14(5):931-942. PubMed ID: 33008758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional Use of Prostacyclin Analogs in Patients With Pulmonary Arterial Hypertension: A Meta-Analysis.
    Wang P; Deng J; Zhang Q; Feng H; Zhang Y; Lu Y; Han L; Yang P; Deng Z
    Front Pharmacol; 2022; 13():817119. PubMed ID: 35222031
    [No Abstract]   [Full Text] [Related]  

  • 9. [Impact of composite clinical worsening events on outcome of patients with pulmonary arterial hypertension associated with congenital heart disease].
    Xu ZY; Zhang HS; Li QQ; Zhang C; Gu H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Mar; 50(3):282-288. PubMed ID: 35340148
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety of sildenafil treatment in pulmonary arterial hypertension: a systematic review.
    Wang RC; Jiang FM; Zheng QL; Li CT; Peng XY; He CY; Luo J; Liang ZA
    Respir Med; 2014 Mar; 108(3):531-7. PubMed ID: 24462476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination Therapy for Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis.
    Fox BD; Shtraichman O; Langleben D; Shimony A; Kramer MR
    Can J Cardiol; 2016 Dec; 32(12):1520-1530. PubMed ID: 27378592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of sequential combination therapy for pulmonary arterial hypertension: A meta-analysis of Randomized-Controlled Trials.
    Tan Z; Wu PY; Zhu TT; Su W; Fang ZF
    Pulm Pharmacol Ther; 2022 Oct; 76():102144. PubMed ID: 35918025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis.
    Lajoie AC; Lauzière G; Lega JC; Lacasse Y; Martin S; Simard S; Bonnet S; Provencher S
    Lancet Respir Med; 2016 Apr; 4(4):291-305. PubMed ID: 26935844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are hemodynamics surrogate end points in pulmonary arterial hypertension?
    Ventetuolo CE; Gabler NB; Fritz JS; Smith KA; Palevsky HI; Klinger JR; Halpern SD; Kawut SM
    Circulation; 2014 Aug; 130(9):768-75. PubMed ID: 24951771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effectiveness of Pharmacologic Interventions for Pulmonary Arterial Hypertension: A Systematic Review and Network Meta-Analysis.
    Jain S; Khera R; Girotra S; Badesch D; Wang Z; Murad MH; Blevins A; Schmidt GA; Singh S; Gerke AK
    Chest; 2017 Jan; 151(1):90-105. PubMed ID: 27615023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Chronic Digoxin Use on Mortality and Heart Failure Hospitalization in Pulmonary Arterial Hypertension.
    Chang KY; Giorgio K; Schmitz K; Walker RF; Prins KW; Pritzker MR; Archer SL; Lutsey PL; Thenappan T
    J Am Heart Assoc; 2023 Mar; 12(6):e027559. PubMed ID: 36892094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of the treat-repair-treat strategy for severe pulmonary arterial hypertension associated with congenital heart disease: a meta-analysis.
    Wang Z; Li X; Li M; Peng J; Zhang H
    BMC Cardiovasc Disord; 2023 Nov; 23(1):569. PubMed ID: 37986143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Outcomes in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta-Analyses of Randomized, Controlled Trials and Observational Registries.
    Khanna D; Zhao C; Saggar R; Mathai SC; Chung L; Coghlan JG; Shah M; Hartney J; McLaughlin V
    Arthritis Rheumatol; 2021 May; 73(5):837-847. PubMed ID: 33538058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effect of sildenafil on treating paediatric pulmonary arterial hypertension: a meta-analysis on the randomised controlled trials.
    Zhang Q; Xu B; Lv J; Wang Z; Du J
    Cardiol Young; 2020 Dec; 30(12):1882-1889. PubMed ID: 33077013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do Patients With Low-Risk Pulmonary Arterial Hypertension Really Benefit From Upfront Combination Therapy?: Insight From the AMBITION Trial.
    Fauvel C; Liu Y; Correa-Jaque P; Kanwar MK; Vizza CD; Lin S; Benza RL
    Chest; 2023 Dec; 164(6):1518-1530. PubMed ID: 37356711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.